VolitionRx Limited (NYSE AMERICAN: VNRX) has announced its financial results for the fourth quarter and full fiscal year 2025, showcasing a remarkable year-over-year revenue growth of 133% in Q4 and a total revenue of $1.7 million for the year, representing a 40% increase compared to the previous year. The company also reported a reduction in operating expenses by $4.8 million, or 17%, and a 14% decrease in net loss compared to 2024. Cameron Reynolds, President and Group CEO, expressed pride in the company's progress towards its goal of improving patient outcomes through earlier detection of diseases. Notably, VolitionRx received its first order for the Nu.Q Cancer assays for clinical certification and announced the inclusion of its Nu.Q NETs assay in a government-backed program in France aimed at early detection of sepsis, valued at approximately $7.3 million. The company is currently in discussions with leading diagnostic and liquid biopsy companies to secure licensing agreements, anticipating further human licensing deals in the near future. A conference call is scheduled for April 1, 2026, to discuss these results and future milestones.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.